3-氧代-N-(2-丙炔-1-基)丁酰胺 | 60557-23-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-氧代-N-(2-丙炔-1-基)丁酰胺
• 英文名称: N-propargylacetoacetamide
• 英文别名: 3-oxo-N-prop-2-ynyl-butanamide；3-oxo-N-(prop-2-yn-1-yl)butanamide；N-Propargylacetoacetamid；3-oxo-N-propargylbutanamide；acetoacetic propargylamide；3-oxo-N-prop-2-ynylbutanamide
• CAS: 60557-23-5
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: PNLNSQKNBYWJDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氧代-N-(2-丙炔-1-基)丁酰胺 在 gold(III) chloride 作用下， 以 乙腈 为溶剂， 反应 16.0h， 生成 1-(5-methyloxazol-2-yl)propan-2-one
  参考文献：
  名称：

  [EN] HERBICIDAL COMPOUNDS
  [FR] COMPOSÉS HERBICIDES

  摘要：

  本发明涉及具有除草活性的噻二唑衍生物，以及用于制备这种衍生物的过程和中间体。该发明还涉及包含这种衍生物的除草组合物，以及在控制不良植物生长方面使用这种化合物和组合物，特别是在控制杂草方面，在有用植物作物中的应用。

  公开号：

  WO2020099404A1
• 作为产物：
  描述：

  双乙烯酮 、 炔丙胺 以 四氢呋喃 为溶剂， 反应 15.0h， 以82%的产率得到3-氧代-N-(2-丙炔-1-基)丁酰胺
  参考文献：
  名称：

  Gold- and Silver-Mediated Cycloisomerizations of N-Propargylamides

  摘要：

  Substituted N-propargylamides have proven to be valuable substrates for alkyne-activated cycloisomerization reactions. N-Tosyl-N'-propargylurea underwent reaction with AuCl3 to give the corresponding dihydroimidazolone, while N-propargyl-3-oxobutanamides and esters were used to construct furanyl fused pyrrolldinones and dihydrofuranones via Ag(I)-mediated alkyne activation.

  DOI：

  10.1021/ol801847j

文献信息

• [EN] CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS<br/>[FR] DÉRIVÉS DE DIARYLBORON CYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'INFLAMMASOME NLRP3
  申请人：UNIV MANCHESTER

  公开号：WO2017017469A1

  公开（公告）日：2017-02-02

  Inhibitor compounds are disclosed. The compounds are effective in the treatment of diseases or conditions in which interleukin 1 β activity is implicated. Methods of synthesis of the compounds, as well as pharmaceutical compositions comprising the compounds are also disclosed.

  抑制剂化合物已被披露。这些化合物在治疗与白细胞介素1β活性有关的疾病或症状中具有有效性。此外，还披露了合成这些化合物的方法，以及包含这些化合物的药物组合物。
• Design and Synthesis of Multi-Functional Ligands through Hantzsch Reaction: Targeting Ca2+ Channels, Activating Nrf2 and Possessing Cathepsin S Inhibitory, and Antioxidant Properties
  作者：Irene Pachón-Angona、Paul J. Bernard、Alexey Simakov、Maciej Maj、Krzysztof Jozwiak、Anna Novotna、Carina Lemke、Michael Gütschow、Helene Martin、María-Jesús Oset-Gasque、José-Marco Contelles、Lhassane Ismaili

  DOI：10.3390/pharmaceutics16010121

  日期：——

  This work relates to the design and synthesis of a series of novel multi-target directed ligands (MTDLs), i.e., compounds 4a–l, via a convenient one-pot three-component Hantzsch reaction. This approach targeted calcium channel antagonism, antioxidant capacity, cathepsin S inhibition, and interference with Nrf2 transcriptional activation. Of these MTDLs, 4i emerged as a promising compound, demonstrating robust antioxidant activity, the ability to activate Nrf2-ARE pathways, as well as calcium channel blockade and cathepsin S inhibition. Dihydropyridine 4i represents the first example of an MTDL that combines these biological activities.

  这项工作涉及通过便捷的一锅三组份汉兹奇反应设计和合成一系列新型多靶点配体（MTDLs），即化合物 4a-l。这种方法的目标是钙通道拮抗、抗氧化能力、抑制 cathepsin S 和干扰 Nrf2 转录激活。在这些 MTDLs 中，4i 是一种很有前途的化合物，它具有很强的抗氧化活性、激活 Nrf2ARE 通路的能力、钙通道阻断能力和 cathepsin S 抑制能力。二氢吡啶 4i 是第一个兼具这些生物活性的 MTDL 实例。
• N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3778569A1

  公开（公告）日：2021-02-17

  A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

  一种含N-杂环五元环的噬菌体蛋白组装抑制剂及其药物组合物和用途，具体涉及一种由式I表示的化合物、其立体异构体、同分异构体、几何异构体、溶解物、活性代谢物、水合物、原药或药学上可接受的盐、其药物组合物及其医疗用途。医疗用途包括用于治疗受益于噬菌体蛋白组装抑制剂的疾病，特别是乙型肝炎病毒感染引起的疾病。
• Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors
  申请人：The University of Manchester

  公开号：US10570157B2

  公开（公告）日：2020-02-25

  Inhibitor compounds are disclosed. The compounds are effective in the treatment of diseases or conditions in which interleukin 1 β activity is implicated. Methods of synthesis of the compounds, as well as pharmaceutical compositions comprising the compounds are also disclosed.

  本研究公开了抑制剂化合物。这些化合物可有效治疗白细胞介素 1 β 活性相关的疾病或病症。此外，还公开了这些化合物的合成方法以及包含这些化合物的药物组合物。
• Triazolyl tryptoline derivatives as β-secretase inhibitors
  作者：Jutamas Jiaranaikulwanitch、Chantana Boonyarat、Valery V. Fokin、Opa Vajragupta

  DOI：10.1016/j.bmcl.2010.09.043

  日期：2010.11

  Tryptoline, a core structure of ochrolifuanine E, which is a hit compound from virtual screening of the Thai herbal database against BACE1 was used as a scaffold for the design of BACE1 inhibitors. The tryptoline was linked with different side chains by 1,2,3-triazole ring readily synthesized by catalytic azide-alkyne cycloaddition reactions. Twenty two triazolyl tryptoline derivatives were synthesized and screened for the inhibitory action against BACE1. JJCA-140 was the most potent inhibitor (IC(50) = 1.49 mu M) and was 100 times more selective for BACE1 than for Cat-D. (C) 2010 Elsevier Ltd. All rights reserved.